Immunotherapeutic Drugs, Devices & Patient Enablement

Thursday, October 25, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Oct. 24, 2018 /PRNewswire/ -- The administration of therapeutic immune modulators is becoming an increasingly important

healthcare treatment option for a growing number diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully
navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration.  Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.Download the full report: https://www.reportbuyer.com/product/5598600 What You Will Learn What approved immunotherapeutic drugs are indicated for self-administration, what is the as-supplied packaging, what are the device specifics, and who markets them? What are the major factors driving the migration of infusible immunotherapeutic drugs to formulations that can be packaged and administered subcutaneously? What is the size of the market for self-administered immunotherapeutic drugs today, who are the market share leaders, and what will the market share be in 2022? How important are drug developer-device manufacturer relationships and what are the key alliances in the industry? What are the essential design factors, technologies and market development issues for devices that can deliver injectable immunotherapeutics subcutaneously? What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?Download the full report: https://www.reportbuyer.com/product/5598600 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/immunotherapeutic-drugs-devices--patient-enablement-300737201.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store